TAFRO syndrome and immune thrombocytopenia (ITP): cross-border specialty drug access for international patients

Quick orientation

TAFRO syndrome is ultra-rare. Immune thrombocytopenia affects an estimated 50 to 100 per 1 million adults, with higher pediatric incidence.

Typical age of onset. All ages; subtype-specific.

Severity tiers. TAFRO is severe and life-threatening at presentation; ITP severity is graded by platelet count and bleeding.

Why specialty drugs for TAFRO syndrome and immune thrombocytopenia (ITP) are hard to access internationally

Doptelet, Tavalisse, and other newer thrombopoietin receptor agonists or syk inhibitors expand options for ITP. Tabrecta and other narrowly-defined products for related Castleman-spectrum disease have narrower global registration.

Treatments approved by the FDA

• Piasky (crovalimab) — FDA approval: 2024. Mechanism: Complement C5 inhibitor (paroxysmal nocturnal hemoglobinuria label; complement-driven hematology relevance). Route: Subcutaneous injection every 4 weeks. US WAC ballpark: Approximately USD 350,000 per year. Country pricing: Qatar · Kuwait · Bahrain · Oman · Lebanon.
• Rezlidhia (olutasidenib) — FDA approval: 2022. Mechanism: IDH1 inhibitor for relapsed/refractory AML (adjacent hematology). Route: Oral twice daily. US WAC ballpark: Approximately USD 280,000 per year. Country pricing: Egypt · Jordan · Bahrain · Oman.
• Rytelo (imetelstat) — FDA approval: 2024. Mechanism: Telomerase inhibitor for transfusion-dependent low-risk MDS (adjacent hematology). Route: Intravenous infusion every 4 weeks. US WAC ballpark: Approximately USD 200,000 per year. Country pricing: Saudi Arabia · Egypt.
• Wayrilz (rilzabrutinib) — FDA approval: 2025. Mechanism: BTK inhibitor (immune thrombocytopenia label, recent). Route: Oral. US WAC ballpark: Approximately USD 250,000 per year. Country pricing: Qatar · Lebanon.

Cross-border pathways used for TAFRO syndrome and immune thrombocytopenia (ITP)

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm specific diagnosis (TAFRO, ITP, Castleman-spectrum, or adjacent).
• Document prior therapy and disease activity.
• Hematology specialist co-management is essential.
• Watch for class-specific adverse events.
• Some products require complement vaccinations before initiation.

Common questions

How rare is TAFRO syndrome?

TAFRO is ultra-rare; treatment is individualized and often combines multiple agents.

Is Wayrilz approved for ITP?

Yes, recently FDA-approved for adult chronic ITP.

Are these drugs available locally?

Registration varies. We confirm by destination.

How long does shipment take?

Five to fifteen business days from prescription receipt.

What documents are required?

Hematologist's prescription, diagnosis confirmation, and treatment history.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For TAFRO syndrome and immune thrombocytopenia (ITP), our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for TAFRO syndrome and immune thrombocytopenia (ITP)

Reserved for you.